This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
September 2026 consolidated quarter: revenue up 282% year on year, net loss narrows to Rs 2,439 lakh
SPARC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts less than Nifty Microcap 250 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
On a consolidated basis for the quarter ended September 30, 2026, revenue from operations rose 282% to Rs 3,003 lakh from Rs 786 lakh a year earlier, while net loss narrowed 68% to Rs 2,439 lakh from Rs 7,585 lakh. For the half year, consolidated revenue was Rs 6,995 lakh versus Rs 1,750 lakh, and net loss was Rs 4,517 lakh versus Rs 12,772 lakh. No exceptional item. Half-year operating cash flow was positive Rs 168,497 lakh after voucher sale.
SPARC remains loss-making despite revenue growth. Cash flow is strong after the voucher sale; 38.51 million warrants may dilute holders.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹30.03 Cr | ₹7.86 Cr | +282.1% |
| Operating profit | −₹47.93 Cr | −₹75.80 Cr | loss narrowed |
| Profit after tax | −₹24.39 Cr | −₹75.85 Cr | loss narrowed |
| EBITDA margin | -151.9% | -836.1% | +684.3 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.